Nebenwirkungen · Cancidas (previously Caspofungin MSD)
CANCIDAS 50 mg powder for concentrate for solution for infusion CANCIDAS 70 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 8
HOS-109329 · Präparat HOS-093179
Caspofungin has also been evaluated at 150 mg daily (for up to 51 days) in 100 adult patients (see section 5.1). The study compared caspofungin at 50 mg daily (following a 70-mg loading dose on Day 1) versus 150 mg daily in the treatment of invasive candidiasis. In this group of patients, the safety of caspofungin at this higher dose appeared generally similar to patients receiving the 50-mg daily dose of caspofungin. The proportion of patients with a serious drug-related adverse reaction or a drug-related adverse reaction leading to caspofungin discontinuation was comparable in the 2 treatment groups.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-08T16:40:00Z · SHA-256 6dd11a424b362e655ce61e4c49586bb6e658af1133d504982e2602258f5f83f7 · Passage 2de79d93d915f25f54273bcae0576b215e06da5f786bbfb9fda80c8f017a1e73 · Zeichen 11309–11918 im Abschnitt